Corcept Therapeutics Incorporated (BIT:1CORT)

Market Cap	6.24B
Revenue (ttm)	634.17M
Net Income (ttm)	122.60M
Shares Out	n/a
EPS (ttm)	1.06
PE Ratio	50.91
Forward PE	41.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	59.50
Previous Close	59.50
Day's Range	59.50 - 59.50
52-Week Range	58.92 - 65.06
Beta	n/a
RSI	63.03
Earnings Date	Jul 30, 2025

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CORT

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD